Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Post by r0naldon Dec 29, 2020 8:30am
246 Views
Post# 32190016

Takeover talks with Bausch Health?

Takeover talks with Bausch Health?

Arbitration award soon to be expected and Cipher still discussing an agreement with Bausch.
Could these talks be about a takeover I wonder?

As we know Cipher has told us (in september?) they were in the final stages of closing a distribution deal.
Nothing since.
Then in the Q3 call we were told they are working on a tax loss deal.
Nothing since.

Pretty sure any distribution deal or tax loss deal Cipher closes would be a pain in the #ss of Bausch if they have any takeover plans.
Bausch could distribute anything Cipher has in their portfolio and could probably find ways using Ciphers tax loss.

Bausch probably would have to pay big time when the arbitrator rules. And they know it.
Better buy Cipher for a known amount and get their business and tax loss too.

I'm really starting to think that talks with Bausch are the cause of (promised) Cipher deals not being closed yet.

So, lets talk numbers. $3? ;)
 

<< Previous
Bullboard Posts
Next >>